Accelerating and Streamlining Microbial Process Development With a Novel Technology (Sept 2026)

This executive summary examines how FUJIFILM Biotechnologies' ShunzymeX™ platform addresses the purification challenges that make microbial expression systems slower and less predictable than monoclonal antibody workflows. Andrei Soliakov, PhD, a principal technical project lead of process development at FUJIFILM Biotechnologies, details the engineering of a scarless protease developed in partnership with the University of Edinburgh, along with proof-of-concept results across four structurally diverse model proteins. Readers will see how a standardized downstream workflow shortens the path from expression strain to GMP manufacturing.